NCT00070382 - Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

November 30, 2003

Conditions

AnemiaLeukemiaLymphomaLymphoproliferative DisorderMultiple Myeloma and Plasma Cell NeoplasmPrecancerous/Nonmalignant ConditionUnspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

darbepoetin alfa

darbepoetin alfa administered at a dose of 200ug once every 2 weeks over a 16-week treatment period

DRUG

epoetin alfa

epoetin alfa administered at a dose of 40,000U once every week over a 16-week treatment period

Trial Locations (1)

90095

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles